We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Northern 2 Vct Plc | LSE:NTV | London | Ordinary Share | GB0005356430 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 54.50 | 53.00 | 56.00 | 54.50 | 54.50 | 54.50 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Investors, Nec | -2.96M | -3.46M | -0.0177 | -30.79 | 106.47M |
TIDMNTV 17 JULY 2018 NORTHERN 2 VCT PLC UNAUDITED NET ASSET VALUE AS AT 30 JUNE 2018 Northern 2 VCT PLC ("the Company") is a Venture Capital Trust ("VCT") launched in 1999 and managed by NVM Private Equity LLP. The Company's objective is to provide high long-term tax-free returns to investors through a combination of dividend yield and capital growth, by investing in a portfolio of investments mainly comprising unquoted venture capital holdings. In order to maintain approval by HM Revenue & Customs as a VCT, the Company is required to comply on a continuing basis with the provisions of Section 274 of the Income Tax Act 2007. The unaudited net asset value per ordinary share as at 30 June 2018 was 66.7 pence (31 March 2018 (audited) 66.9 pence). The net asset value is stated before deducting the final dividend of 3.5 pence per share in respect of the year ended 31 March 2018, which will be paid to eligible shareholders on 20 July 2018. For the purposes of calculating the net asset value per share, quoted investments are carried at bid price as at 30 June 2018 and unquoted investments are carried at fair value as at 30 June 2018 as determined by the directors. During the three months ended 30 June 2018 the following new venture capital investments were completed: Amount invested Name of company Business activity GBP000 ----------------- ----------------------------------------------------------- --------- Ablatus Therapeutics Development of medical devices to treat cancerous Limited tumours 322 Software solution to automate the preparation of documents Clarilis Limited for the legal sector 1,012 Newcells Biotech Development of innovative efficacy and toxicity testing Limited solutions for the drug discovery sector 484 The number of ordinary shares in issue at 30 June 2018 was 130,089,490. During the three months ended 30 June 2018 there were no movements in the number of shares in issue. Enquiries: Simon John/James Bryce, NVM Private Equity LLP -- 0191 244 6000 Website: www.nvm.co.uk Neither the contents of the NVM Private Equity LLP website nor the contents of any website accessible from hyperlinks on the NVM Private Equity LLP website (or any other website) is incorporated into, or forms part of, this announcement.
(END) Dow Jones Newswires
July 17, 2018 05:30 ET (09:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Northern 2 Vct Chart |
1 Month Northern 2 Vct Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions